What is B. Riley’s Estimate for CGTX FY2025 Earnings?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Analysts at B. Riley issued their FY2025 EPS estimates for shares of Cognition Therapeutics in a research note issued on Tuesday, November 26th. B. Riley analyst M. Mamtani expects that the company will post earnings per share of ($0.83) for the year. B. Riley has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.93) per share.

Several other research analysts have also issued reports on the stock. Chardan Capital restated a “buy” rating and set a $11.00 price target on shares of Cognition Therapeutics in a report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Cognition Therapeutics in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Cognition Therapeutics Stock Performance

Cognition Therapeutics stock opened at $0.40 on Wednesday. Cognition Therapeutics has a 52-week low of $0.34 and a 52-week high of $2.95. The firm has a 50 day moving average price of $0.47 and a two-hundred day moving average price of $1.12. The firm has a market cap of $16.53 million, a price-to-earnings ratio of -0.41 and a beta of 1.34.

Institutional Trading of Cognition Therapeutics

Several hedge funds have recently modified their holdings of CGTX. Virtu Financial LLC bought a new stake in shares of Cognition Therapeutics in the 3rd quarter valued at $27,000. Bangor Savings Bank grew its position in Cognition Therapeutics by 41.6% in the 2nd quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock valued at $56,000 after purchasing an additional 10,000 shares during the period. Sigma Planning Corp grew its position in Cognition Therapeutics by 14.6% in the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after purchasing an additional 25,050 shares during the period. Mercer Global Advisors Inc. ADV grew its position in Cognition Therapeutics by 33.4% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after purchasing an additional 24,050 shares during the period. Finally, CM Management LLC grew its position in Cognition Therapeutics by 14.3% in the 2nd quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $332,000 after purchasing an additional 25,000 shares during the period. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.